Probing brain circuit and behavior with protein:protein interaction modulators

用蛋白质探测大脑回路和行为:蛋白质相互作用调节剂

基本信息

  • 批准号:
    10607051
  • 负责人:
  • 金额:
    $ 82.42万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2023
  • 资助国家:
    美国
  • 起止时间:
    2023-02-01 至 2026-11-30
  • 项目状态:
    未结题

项目摘要

ABSTRACT Psychiatric diseases are complex brain disorders associated with maladaptive plasticity of the brain circuit for which we lack predictive preclinical measures of clinical efficacy. To fill this gap, we need to use molecular knowledge to inform development of novel probes in order to interrogate the mechanisms that underlie circuit deficits in these disorders and drive advanced therapeutic design. Protein-protein interactions (PPI) within ion channel complexes fine-tune neuronal excitability and are emerging as links to the biology of psychiatric disorders. Their highly specific and flexible interfaces make protein-channel interactions ideal targets for probe development. Such molecular probes would provide the neuropharmacology community with optimal research tools to parse out brain disease complexities and enable more effective drug design. We have identified the PPI between the voltage-gated Na+ (Nav) Nav1.6 channel and its accessory regulator protein, fibroblast growth factor 14 (FGF14) as a functionally relevant regulator of excitability of medium spiny neurons (MSN) in the nucleus accumbens (NAc); a central component of the mesocorticolimbic circuit whose dysfunction has been associated with a wide spectrum of neuropsychiatric disorders. Through a bioluminescence-based high-throughput screen (HTS) and a round of chemical optimization we have identified the new brain permeable probe 1028 that modulates FGF14:Nav1.6 channel complex formation and increases Nav1.6 channel availability and MSN firing. When systemically administrated, 1028 increases accumbal neuron firing and promotes hedonic states in situations lacking motivation, suggesting the compound can modulate reward-related behaviors within the mesocorticolimbic circuit. Here, we are proposing to further optimize 1028 for in vivo use by improving its potency and metabolic stability and determine its mechanism of action at the molecular (Aim 1), cellular (Aim 2), circuital, and behavioral levels (Aim 3). Outcomes of this proposed research will generate the first-in-class brain-permeant chemical probes to interrogate the reward circuit, providing the foundation for pre-therapeutic development of a new class of PPI-based leads for a broad spectrum of psychiatric disorders.
摘要 精神疾病是与脑回路的适应不良可塑性相关的复杂脑障碍, 我们缺乏临床疗效的预测性临床前测量。为了填补这一空白,我们需要使用分子 为新型探针的开发提供信息的知识,以便询问电路的基础机制 这些疾病的缺陷,并推动先进的治疗设计。离子内蛋白质-蛋白质相互作用(PPI) 通道复合物微调神经元的兴奋性,并正在成为精神疾病的生物学联系。 紊乱它们的高度特异性和灵活的界面使蛋白质-通道相互作用成为探针的理想靶点 发展这样的分子探针将为神经药理学界提供最佳的研究 分析大脑疾病的复杂性并实现更有效的药物设计的工具。 我们已经确定了电压门控Na+(Nav)Nav1.6通道及其辅助调节器之间的PPI 蛋白质,成纤维细胞生长因子14(FGF 14)作为功能相关的调节介质棘的兴奋性 神经元(MSN)在脑桥核(NAc);中皮质边缘回路的中央组成部分, 功能障碍与广泛的神经精神障碍有关。通过 基于生物发光的高通量筛选(HTS)和一轮化学优化,我们已经确定 新的脑可渗透探针1028,其调节FGF 14:Nav1.6通道复合物的形成并增加 Nav1.6频道可用性和MSN射击。当全身给药时,1028增加了 在缺乏动机的情况下,神经元放电并促进享乐状态,这表明该化合物可以 调节中皮层边缘回路中与奖赏相关的行为。在此,我们建议进一步 通过提高其效力和代谢稳定性优化1028用于体内使用,并确定其 在分子(目标1)、细胞(目标2)、电路和行为水平(目标3)发挥作用。这件事的结果 拟议中的研究将产生一流的大脑渗透化学探针,以询问奖励 电路,为治疗前开发一类新的基于PPI的电极导线提供基础,用于广泛的 一系列精神疾病

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Fernanda Laezza其他文献

Fernanda Laezza的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Fernanda Laezza', 18)}}的其他基金

Brain derived extracellular vesicles-mediated neurotoxicity of deltamethrin
溴氰菊酯脑源性细胞外囊泡介导的神经毒性
  • 批准号:
    10679858
  • 财政年份:
    2023
  • 资助金额:
    $ 82.42万
  • 项目类别:
Neurotrophin-dependent regulation of voltage-gated sodium channels
电压门控钠通道的神经营养蛋白依赖性调节
  • 批准号:
    10443551
  • 财政年份:
    2020
  • 资助金额:
    $ 82.42万
  • 项目类别:
Neurotrophin-dependent regulation of voltage-gated sodium channels
电压门控钠通道的神经营养蛋白依赖性调节
  • 批准号:
    10615846
  • 财政年份:
    2020
  • 资助金额:
    $ 82.42万
  • 项目类别:
Neurotrophin-dependent regulation of voltage-gated sodium channels
电压门控钠通道的神经营养蛋白依赖性调节
  • 批准号:
    10183336
  • 财政年份:
    2020
  • 资助金额:
    $ 82.42万
  • 项目类别:
Discovery of Chemical Probes for Psychiatric Disorders and Addiction
发现精神疾病和成瘾的化学探针
  • 批准号:
    9252858
  • 财政年份:
    2016
  • 资助金额:
    $ 82.42万
  • 项目类别:
Discovery of Chemical Probes for Psychiatric Disorders and Addiction
发现精神疾病和成瘾的化学探针
  • 批准号:
    9353468
  • 财政年份:
    2016
  • 资助金额:
    $ 82.42万
  • 项目类别:
Validation of FGF14 as a New Molecular Target of GSK3
验证 FGF14 作为 GSK3 的新分子靶点
  • 批准号:
    8838257
  • 财政年份:
    2012
  • 资助金额:
    $ 82.42万
  • 项目类别:
Validation of FGF14 as a New Molecular Target of GSK3
验证 FGF14 作为 GSK3 的新分子靶点
  • 批准号:
    9061830
  • 财政年份:
    2012
  • 资助金额:
    $ 82.42万
  • 项目类别:
Validation of FGF14 as a New Molecular Target of GSK3
验证 FGF14 作为 GSK3 的新分子靶点
  • 批准号:
    8660342
  • 财政年份:
    2012
  • 资助金额:
    $ 82.42万
  • 项目类别:
Validation of FGF14 as a New Molecular Target of GSK3
验证 FGF14 作为 GSK3 的新分子靶点
  • 批准号:
    8373279
  • 财政年份:
    2012
  • 资助金额:
    $ 82.42万
  • 项目类别:

相似海外基金

Transcriptional assessment of haematopoietic differentiation to risk-stratify acute lymphoblastic leukaemia
造血分化的转录评估对急性淋巴细胞白血病的风险分层
  • 批准号:
    MR/Y009568/1
  • 财政年份:
    2024
  • 资助金额:
    $ 82.42万
  • 项目类别:
    Fellowship
Combining two unique AI platforms for the discovery of novel genetic therapeutic targets & preclinical validation of synthetic biomolecules to treat Acute myeloid leukaemia (AML).
结合两个独特的人工智能平台来发现新的基因治疗靶点
  • 批准号:
    10090332
  • 财政年份:
    2024
  • 资助金额:
    $ 82.42万
  • 项目类别:
    Collaborative R&D
Acute senescence: a novel host defence counteracting typhoidal Salmonella
急性衰老:对抗伤寒沙门氏菌的新型宿主防御
  • 批准号:
    MR/X02329X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 82.42万
  • 项目类别:
    Fellowship
Cellular Neuroinflammation in Acute Brain Injury
急性脑损伤中的细胞神经炎症
  • 批准号:
    MR/X021882/1
  • 财政年份:
    2024
  • 资助金额:
    $ 82.42万
  • 项目类别:
    Research Grant
KAT2A PROTACs targetting the differentiation of blasts and leukemic stem cells for the treatment of Acute Myeloid Leukaemia
KAT2A PROTAC 靶向原始细胞和白血病干细胞的分化,用于治疗急性髓系白血病
  • 批准号:
    MR/X029557/1
  • 财政年份:
    2024
  • 资助金额:
    $ 82.42万
  • 项目类别:
    Research Grant
Combining Mechanistic Modelling with Machine Learning for Diagnosis of Acute Respiratory Distress Syndrome
机械建模与机器学习相结合诊断急性呼吸窘迫综合征
  • 批准号:
    EP/Y003527/1
  • 财政年份:
    2024
  • 资助金额:
    $ 82.42万
  • 项目类别:
    Research Grant
FITEAML: Functional Interrogation of Transposable Elements in Acute Myeloid Leukaemia
FITEAML:急性髓系白血病转座元件的功能研究
  • 批准号:
    EP/Y030338/1
  • 财政年份:
    2024
  • 资助金额:
    $ 82.42万
  • 项目类别:
    Research Grant
STTR Phase I: Non-invasive focused ultrasound treatment to modulate the immune system for acute and chronic kidney rejection
STTR 第一期:非侵入性聚焦超声治疗调节免疫系统以治疗急性和慢性肾排斥
  • 批准号:
    2312694
  • 财政年份:
    2024
  • 资助金额:
    $ 82.42万
  • 项目类别:
    Standard Grant
ロボット支援肝切除術は真に低侵襲なのか?acute phaseに着目して
机器人辅助肝切除术真的是微创吗?
  • 批准号:
    24K19395
  • 财政年份:
    2024
  • 资助金额:
    $ 82.42万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Acute human gingivitis systems biology
人类急性牙龈炎系统生物学
  • 批准号:
    484000
  • 财政年份:
    2023
  • 资助金额:
    $ 82.42万
  • 项目类别:
    Operating Grants
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了